Dawei Yue

Dawei Yue currently serves as CEO of AxisPharm, a company focused on ADC linker products and services, since April 2018. Previously, Dawei Yue held the position of Director of Chemistry at BroadPharm from May 2012 to March 2018, where responsibilities included managing lead optimization for a COPD program and leading a peptides library synthesis project for Pfizer's Covx unit. Prior experience includes serving as Associate Director of Medicinal Chemistry at Crown Bioscience, Inc., from February 2011 to April 2012, focusing on kinase inhibitors and early drug discovery. From January 2006 to January 2011, Dawei Yue worked as a Scientist at Arena Pharmaceuticals, contributing to various metabolic disease treatments and cannabinoid receptor modulators. Academic qualifications include a Ph.D. in Organic Chemistry from Iowa State University and postdoctoral studies at both Scripps Research and UCLA.